Login to Your Account

Clinic Roundup

Tuesday, October 22, 2013

• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in an 18-patient Phase I trial in chronically hepatitis C virus-infected patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription